CoverageForm 410-K10-Q8-K13D13G13F

NOTV · Inotiv, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · NOTV

Income Statement

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$513.02M$490.74M$572.42M$547.66M$89.61M$60.47M
Cost of Revenue----$59.45M$42.23M
Gross Profit----$30.16M$18.24M
R&D----$405.0K$950.0K
SG&A$71.10M$77.03M$108.23M$82.44M$30.38M$16.98M
Total Operating Expenses----$35.77M$21.30M
D&A$55.93M$57.12M$54.72M$49.32M$4.07M$3.93M
Operating Income($30.90M)($86.41M)($81.46M)($263.45M)($5.62M)($3.06M)
Interest Expense$4.28M$46.88M$43.02M$29.70M$1.68M$1.49M
Income Tax($19.14M)($21.88M)($19.34M)($15.19M)($4.78M)$147.0K
Net Income($68.63M)($108.44M)($105.14M)($337.02M)$10.89M($4.68M)
EPS - Basic($2.11)($4.19)($4.10)($13.84)$0.83($0.43)
EPS - Diluted($2.11)($4.19)($4.10)($13.84)$0.19($0.43)

Balance Sheet

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash & Equivalents$21.74M$21.43M$35.49M$18.52M$138.92M$1.41M
Accounts Receivable---$88.87M$20.73M$8.68M
Inventory$45.74M$18.17M$56.10M$71.44M$602.0K$700.0K
Accounts Payable$48.53M$33.53M$32.56M$28.70M$6.16M$3.20M
Current Assets$194.59M$163.41M$213.80M$232.98M$189.02M$15.30M
Total Assets$771.11M$781.36M$856.53M$962.90M$321.86M$61.59M
Current Liabilities$556.78M$119.04M$132.19M$164.10M$55.11M$31.64M
Long-term Debt$0$389.80M$369.80M$330.68M$154.21M$18.83M
Total Liabilities$635.09M$610.86M$588.04M$603.13M$216.73M$54.00M
Stockholders' Equity$136.03M$170.50M$269.15M$360.37M$105.13M$7.60M
Retained Earnings($630.81M)($562.16M)($453.28M)($348.28M)($11.02M)($21.91M)

Cash Flow

Line itemFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow($10.46M)($6.80M)$27.88M($5.22M)$10.75M$1.29M
Investing Cash Flow($12.89M)($16.83M)($28.75M)($333.72M)($54.06M)($10.13M)
Financing Cash Flow$23.70M$9.68M$15.87M$203.15M$198.83M$9.64M
CapEx$16.61M$22.31M$27.50M$36.30M$12.47M$6.20M
Free Cash Flow($27.07M)($29.11M)$380.0K($41.52M)($1.73M)($4.91M)

Ratios

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Profitability
Gross margin----33.7%30.2%
Operating margin-6.0%-17.6%-14.2%-48.1%-6.3%-5.1%
EBITDA margin4.9%-6.0%-4.7%-39.1%-1.7%1.4%
Net margin-13.4%-22.1%-18.4%-61.5%12.2%-7.7%
Free cash flow margin-5.3%-5.9%0.1%-7.6%-1.9%-8.1%
FCF / Net income0.390.27-0.000.12-0.161.05
R&D / Revenue----0.5%1.6%
SG&A / Revenue13.9%15.7%18.9%15.1%33.9%28.1%
Effective tax rate-----78.1%-
Return on assets-8.9%-13.9%-12.3%-35.0%3.4%-7.6%
Return on equity-50.4%-63.6%-39.1%-93.5%10.4%-61.7%
Return on invested capital-17.9%-12.2%-10.1%-30.1%-2.2%-9.2%
Liquidity
Current ratio0.351.371.621.423.430.48
Quick ratio0.271.221.190.983.420.46
Cash ratio0.040.180.270.112.520.04
Leverage
Debt / Equity0.002.291.370.921.472.48
Debt / Assets0.000.500.430.340.480.31
Debt / EBITDA0.00----21.74
Interest coverage-7.2x-1.8x-1.9x-8.9x-3.3x-2.1x
Equity multiplier5.674.583.182.673.068.11
Liabilities / Assets0.820.780.690.630.670.88
Efficiency
Asset turnover0.670.630.670.570.280.98
Inventory turnover----98.7560.33
Days sales outstanding---59d84d52d
Days inventory outstanding----4d6d
Days payable outstanding----38d28d
Cash conversion cycle----50d31d
Valuation
P / E----153.9x-
P / B0.3x0.3x0.3x1.1x3.9x6.8x
P / S0.1x0.1x0.1x0.7x4.5x0.9x
EV / EBITDA1.0x----80.0x
Growth
Revenue growth (YoY)4.5%-14.3%4.5%511.2%48.2%38.6%
Revenue CAGR (3y)-2.2%76.3%111.5%132.4%50.4%35.6%
Revenue CAGR (5y)53.4%62.3%85.1%86.5%34.4%21.6%
Gross profit growth (YoY)----65.4%41.1%
Operating income growth (YoY)64.2%-6.1%69.1%-4589.4%-83.4%-1902.0%
Net income growth (YoY)36.7%-3.1%68.8%---493.0%
EPS growth (YoY)49.6%-2.2%70.4%---437.5%
EPS CAGR (3y)------
EPS CAGR (5y)------
FCF growth (YoY)7.0%---2305.4%64.8%3.7%
FCF CAGR (5y)---29.4%---
Book value growth (YoY)-20.2%-36.7%-25.3%242.8%1284.0%-29.1%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-09-30.

Business segments

$513.02M total
Research Models And Services Segment$325.08M · 63.4%
Discovery And Safety Assessment Segment$187.94M · 36.6%

Product / service

$513.02M total
Product$280.16M · 54.6%
Service$232.87M · 45.4%

Geographic

$513.02M total
US$447.98M · 87.3%
NL$35.48M · 6.9%
Other Than United States And Netherlands$29.56M · 5.8%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

-0.40
Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

4/9
Neutral
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • Long-term debt decreased
  • Current ratio improved
  • No share dilution
  • -Gross margin improved
  • Asset turnover improved

Peer comparison

Same SIC group: Services-Commercial Physical & Biological Research

CompanyRevenue (last FY)Net marginROE
INCY$5.14B25.0%24.9%
CRL$4.02B-3.6%-4.6%
MEDP$2.53B17.8%98.3%
IQV$16.31B8.3%20.9%
OABI$18.67M-347.0%-24.3%

Comparing Inotiv against the 5 most active filers in the same SIC group.